Vaccines
23 December 2024
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines17 December 2024
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)16 December 2024
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India14 December 2024
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate14 December 2024
PDC*line Pharma Presents Primary Clinical Results From Phase I/II Trial on PDC*lung01 Cancer Vaccine at ESMO-IO 202410 December 2024
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza10 December 2024
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome10 December 2024
First Subject Dosed in Initial Cohort of Phase 2b Clinical Study of CyanVac’s Intranasal COVID-19 Vaccine Candidate3 December 2024
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants28 November 2024
Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate22 November 2024
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans19 November 2024
Uvax Bio Announces Interim Results from a Phase 1 Clinical Trial Evaluating its HIV-1 Vaccine15 November 2024
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease15 November 2024
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V215 November 2024
Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX83613 November 2024
Longhorn Vaccines and Diagnostics Composite Peptide Vaccine Combats Sepsis Related to Antimicrobial Resistant Tuberculosis12 November 2024
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial11 November 2024
Theragent and CellVax Therapeutics Announce First Patient Dosed in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy29 October 2024
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVY25 October 2024
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine23 October 2024
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease17 October 2024
Longhorn Vaccines and Diagnostics Highlights New Data for LHNVD-303 its Bacterial Sepsis Vaccine at IDWeek 202415 October 2024
Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports